LUGARESI, Alessandra
 Distribuzione geografica
Continente #
EU - Europa 134
NA - Nord America 17
AS - Asia 2
AF - Africa 1
Totale 154
Nazione #
IT - Italia 73
FR - Francia 25
SE - Svezia 22
US - Stati Uniti d'America 17
IE - Irlanda 9
UA - Ucraina 3
GB - Regno Unito 2
VN - Vietnam 2
EG - Egitto 1
Totale 154
Città #
Chieti 47
Stockholm 22
Dublin 8
Columbus 4
Bellante 3
San Vito Chietino 3
Codogno 2
Dong Ket 2
Ellicott City 2
Florence 2
Genoa 2
London 2
Paris 2
Pescara 2
Boardman 1
Cairo 1
Cepagatti 1
Council Bluffs 1
Desio 1
Marzabotto 1
Mountain View 1
Penne 1
Petriolo 1
San Mateo 1
Somma Lombardo 1
Teramo 1
Turin 1
Totale 116
Nome #
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population, file e4233f15-053c-2860-e053-6605fe0a460a 19
Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure, file e4233f19-1c35-2860-e053-6605fe0a460a 16
Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study, file e4233f15-06cd-2860-e053-6605fe0a460a 15
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study, file e4233f15-0ba7-2860-e053-6605fe0a460a 13
Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study, file e4233f18-4bec-2860-e053-6605fe0a460a 13
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS, file e4233f19-0192-2860-e053-6605fe0a460a 11
An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis, file e4233f14-e6f5-2860-e053-6605fe0a460a 9
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial, file e4233f15-0613-2860-e053-6605fe0a460a 8
Cleavage of cystatin C is not associated with multiple sclerosis, file e4233f14-eac6-2860-e053-6605fe0a460a 6
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry, file e4233f19-321b-2860-e053-6605fe0a460a 6
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a, file e4233f18-5b85-2860-e053-6605fe0a460a 4
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy, file e4233f14-e7d6-2860-e053-6605fe0a460a 2
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis, file e4233f14-fa93-2860-e053-6605fe0a460a 2
Breastfeeding is not related to postpartum relapses in multiple sclerosis., file e4233f14-fbcf-2860-e053-6605fe0a460a 2
Development of methods for lipid extraction from CSF and application of mass spectometry techniques for the characterization of the lipid profile and neurosteroids levels in MS patients, file e4233f15-05b0-2860-e053-6605fe0a460a 2
Mass spectrometry based metabonomics of the cerebrospinalfluid highlights a correlation between polar lipids and carnitines levels in multiple sclerosis patients., file e4233f15-0699-2860-e053-6605fe0a460a 2
Long-term efficacy and tolerability of natalizumab treatment in multiple sclerosis patients: a multicentre experience in Italy, file e4233f15-0715-2860-e053-6605fe0a460a 2
Teeth loss after teriflunomide treatment: Casual or causal? A short case series, file e4233f17-86c4-2860-e053-6605fe0a460a 2
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder, file e4233f17-df53-2860-e053-6605fe0a460a 2
An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis, file e4233f18-6c65-2860-e053-6605fe0a460a 2
Determinants of therapeutic lag in multiple sclerosis, file e4233f19-024f-2860-e053-6605fe0a460a 2
Comparative efficacy of switching to natalizumab in active multiple sclerosis, file e4233f14-e670-2860-e053-6605fe0a460a 1
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis, file e4233f14-e671-2860-e053-6605fe0a460a 1
Chronic inflammatory demyelinating polyneuropathy in diabetes mellitus, file e4233f14-e6a4-2860-e053-6605fe0a460a 1
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS), file e4233f14-e7d5-2860-e053-6605fe0a460a 1
Patterns of reactivity of human anti-GM1 antibodies with spinal-cord and motor neurons, file e4233f14-ece7-2860-e053-6605fe0a460a 1
Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra, file e4233f14-ed28-2860-e053-6605fe0a460a 1
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry., file e4233f14-f719-2860-e053-6605fe0a460a 1
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial, file e4233f14-f970-2860-e053-6605fe0a460a 1
Fingolimod after natalizumab and the risk of short-term relapse, file e4233f15-051b-2860-e053-6605fe0a460a 1
Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis, file e4233f15-0616-2860-e053-6605fe0a460a 1
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies, file e4233f15-069d-2860-e053-6605fe0a460a 1
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis, file e4233f15-0859-2860-e053-6605fe0a460a 1
Role preferences of relapsing MS patient in Italy, file e4233f15-187d-2860-e053-6605fe0a460a 1
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts, file e4233f19-481b-2860-e053-6605fe0a460a 1
Totale 154
Categoria #
all - tutte 634
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 634


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 0 0 0 0 4 1 0
2020/20219 0 0 1 0 0 0 0 0 1 5 0 2
2021/202226 0 1 4 0 0 2 0 10 2 0 0 7
2022/202334 3 1 0 0 1 15 6 0 3 2 3 0
2023/202460 1 2 3 7 4 11 12 2 13 1 4 0
Totale 154